Pfizer Inc. and Eli Lilly and Company launched a call for proposals for the 2nd Global Awards for Advancing Chronic Pain Research (ADVANCE).

ADVANCE is a competitive awards program and will provide the opportunity for Pfizer Inc. and Eli Lilly and Company to support chronic pain research at medical and research institutions throughout the world.

Proposals will be reviewed by an external multidisciplinary, Independent Review Committee comprising renowned, global experts in chronic pain. The assessment process is completely independent of Pfizer Inc. and Eli Lilly and Company, with final responsibility for selection of Awardees resting with the Co-Chairs.

The intent of the program is to fund approximately 5 grants between US $50,000 and US $200,000, from a total fund of US $1 million.

Please find here the ADVANCE Grant Program Flyer with all the information on application and selection criteria.

For further information about ADVANCE, including how to apply, please visit

Application Deadline: August 8, 2019

Subscribe to the European Pain Federation Newsletter!

Don't worry, we will not spam you, you can unsubscribe at any time.

For more information on the transmission and use of your personal data, please refer to our privacy policy.Pr.

You have Successfully Subscribed!